Drug Profile
GBT 014
Alternative Names: GBT014Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Genbiotech
- Class Proteins
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cartilage disorders
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Cartilage disorders in France (Parenteral)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Cartilage-disorders in France (Parenteral)
- 05 Feb 2014 Preclinical trials in Cartilage disorders in France (Parenteral)